Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMT-358
- Development stage
- Phase 4
- Lead developer
- IMMEDIATE Therapeutics
- Administration
- Intravenous
01
Overview
**IMT-358** is an investigational, proprietary glucose-insulin-potassium metabolic stabilization therapy developed by IMMEDIATE Therapeutics for rapid intravenous administration at first medical contact in acute coronary syndrome. The fixed-dose GIK formulation is intended to support myocardial cellular energy balance during early ischemia, before definitive reperfusion, with the goal of reducing downstream myocardial injury, cardiac arrest, heart-failure hospitalization, and mortality. The program is supported by the NIH-funded IMMEDIATE trial of early intravenous GIK and is described by the developer as Phase 3-ready with FDA Breakthrough Therapy designation for acute coronary syndrome. ([immtx.com](https://immtx.com/))
- Other names
- glucose-insulin-potassiumGIK solutionIMMEDIATE trial GIK
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on IMT-358.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMT-358.